CN111072588B - 一种含硫氰基噻唑啉类化合物的制备方法 - Google Patents

一种含硫氰基噻唑啉类化合物的制备方法 Download PDF

Info

Publication number
CN111072588B
CN111072588B CN201911350702.1A CN201911350702A CN111072588B CN 111072588 B CN111072588 B CN 111072588B CN 201911350702 A CN201911350702 A CN 201911350702A CN 111072588 B CN111072588 B CN 111072588B
Authority
CN
China
Prior art keywords
sulfur
preparation
containing cyano
thiazoline compound
nmr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911350702.1A
Other languages
English (en)
Other versions
CN111072588A (zh
Inventor
郭维斯
张延安
文丽荣
李明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao University of Science and Technology
Original Assignee
Qingdao University of Science and Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qingdao University of Science and Technology filed Critical Qingdao University of Science and Technology
Priority to CN201911350702.1A priority Critical patent/CN111072588B/zh
Publication of CN111072588A publication Critical patent/CN111072588A/zh
Application granted granted Critical
Publication of CN111072588B publication Critical patent/CN111072588B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/10—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

本发明公开了属于有机合成技术领域的一种含硫氰基噻唑啉类化合物的制备方法。所述方法为：向反应器中加入硫代酰胺、硫氰酸铵、溶剂，在通电的作用下反应，反应完毕后，用硅胶柱层析分离得到纯的目标产物。本发明所提供的含硫氰基噻唑啉类化合物的制备方法具有科学合理、条件温和、操作简单、反应时间短等特点。其反应方程式如下：

Description

一种含硫氰基噻唑啉类化合物的制备方法
技术领域
本发明属于有机合成技术领域，具体涉及一种含硫氰基噻唑啉类化合物的制备方法。
背景技术
噻唑啉类化合物作为杂环化合物中重要的一类结构具有广泛的生理活性，经研究表明，此类杂环化合物可以作为谷胱甘肽还原酶抑制剂(Mol.Pharmaceutics 2018,15,3069)、具有抗肿瘤活性(J.Org.Chem.1961,26,3867)以及抗有丝分裂剂(Chem.Rev.2009,109,1371)。同时，硫氰酸酯是一类含有硫氰基官能团的重要化合物,具有多种生物活性,如杀虫(J.Med.Chem.2002,45,3984)、抗微生物(Pharm.Chem.J.2013,47,422)等,在医药和农药等领域有着重要的应用价值，因此，发展一种绿色、高效合成含硫氰基噻唑啉类化合物的新方法具有重要意义。
噻唑啉类化合物的制备方法有：
1)以烯烃、硫代酰胺为原料
Li课题组以烯烃和硫代酰胺为原料，经两步反应制备了噻唑啉类化合物(Org.Lett.2017,19,930)。
2)以苯甲酸、2-氨基乙酸为原料
Seijas课题组以苯甲酸和2-氨基乙酸为原料，加入劳森试剂，在微波高温条件下制备得到噻唑啉类化合物(Tetrahedron.2008,64,9280)。
利用上述方法合成噻唑啉类化合物，具有明显的缺点和不足：1)需要加热；2)操作繁琐；3)反应时间长。
发明内容
为了克服上述现有技术的不足，本发明提供了一种含硫氰基噻唑啉类化合物的制备方法。
一种含硫氰基噻唑啉类化合物的制备方法，所述含硫氰基噻唑啉化合物具有式Ⅰ所示的结构：
Figure GDA0002916071040000021
式Ⅰ中，其中R1选自苯基、4-甲基苯基、4-甲氧基苯基、4-氯苯基、4-溴苯基、4-三氟甲基苯基、2-噻吩基、2-吡啶基且R2和R3选自氢；R1和R2选自苯基且R3选自H；R1和R3选自苯基且R2选自H；其特征在于，向反应器中加入摩尔比为1：2的硫代酰胺与硫氰酸铵，加入乙腈作为溶剂，在电的作用下，室温下搅拌反应，反应方程式如下：
Figure GDA0002916071040000022
本发明的有益效果为：本发明提供的含硫氰基噻唑啉类化合物的合成方法科学合理，建立了一种合成多种取代基的含硫氰基噻唑啉类化合物的新方法；该方法具有原料易得、操作简单、反应条件温和、反应时间短等特点。
附图说明
图1为实施例1制备的化合物3a的NMR图谱；
图2为实施例7制备的化合物3g的NMR图谱；
图3为实施例9制备的化合物3i的NMR图谱。
具体实施方式
下面结合附图和具体的实施例对本发明进一步详细的说明：
下述实施例中所述试验方法，如无特殊说明，均为常规方法；所述试剂和材料，如无特殊说明，均可从商业途径获得。
实施例1
含硫氰基噻唑啉化合物3a的制备
Figure GDA0002916071040000031
向10mL三口瓶中加入N-烯丙基苯并硫代酰胺1a(0.2mmol,36mg)，硫氰酸铵2(0.4mmol,30mg)和乙腈(4mL)。两根石墨棒(Φ5mm)分别作为阳极和阴极。将反应混合物在2V的恒定电压下室温搅拌5小时。反应完成后，用旋转蒸发仪除去溶剂。通过硅胶快速色谱法，使用石油醚和乙酸乙酯作为洗脱液，得到产物3a，产率84％。
谱图解析数据3a:
1H NMR(CDCl3,500MHz):δ7.85–7.78(m,2H),7.46(m,3H),4.64(dd,J＝16.4,2.2,1H),4.41(dd,J＝16.5,7.8,1H),4.27–4.18(m,1H),3.16(dd,J＝13.4,6.5,1H),3.05(dd,J＝13.4,8.2,1H).13C NMR(CDCl3,125MHz):δ166.8,132.6,131.7,128.7,128.4,111.3,68.5,50.1,38.9.HRMS(ESI-TOF,[M+H+]):calcd for C11H11N2S2,235.0364,found235.0369.
实施例2
用1b代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000032
谱图解析数据3b:
1H NMR(CDCl3,500MHz):δ7.79–7.59(m,2H),7.23(d,J＝7.9,2H),4.62(dd,J＝16.4,2.1,1H),4.39(dd,J＝16.4,7.8,1H),4.20(m,1H),3.15(dd,J＝13.4,6.5,1H),3.04(dd,J＝13.4,8.2,1H),2.40(s,3H).13C NMR(CDCl3,125MHz):δ166.7,142.2,129.9,129.4,128.4,111.4,68.4,49.9,38.9,21.5.HRMS(ESI-TOF,[M+H+]):calcd for C12H13N2S2,249.0520,found 249.0524.
实施例3
用1c代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000041
谱图解析数据3c:
1H NMR(CDCl3,500MHz):δ7.80–7.74(m,2H),6.96–6.90(m,2H),4.60(dd,J＝16.3,2.1,1H),4.37(dd,J＝16.2,7.7,1H),4.20(m,1H),3.85(s,3H),3.16(dd,J＝13.4,6.5,1H),3.04(dd,J＝13.4,8.2,1H).13C NMR(CDCl3,125MHz):δ166.0,162.3,130.1,125.3,114.0,111.3,68.3,55.4,50.1.HRMS(ESI-TOF,[M+H+]):calcd for C12H13N2OS2,265.0469,found 265.0475.
实施例4
用1d代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000042
谱图解析数据3d:
1H NMR(CDCl3,500MHz):δ7.75(d,J＝8.4,2H),7.40(d,J＝8.4,2H),4.63(dd,J＝16.5,2.1,1H),4.40(dd,J＝16.5,7.9,1H),4.29–4.21(m,1H),3.16(dd,J＝13.4,6.5,1H),3.05(dd,J＝13.4,8.1,1H).13C NMR(CDCl3,125MHz):δ165.6,137.8,131.0,129.7,128.9,111.2,68.5,50.4,38.8.HRMS(ESI-TOF,[M+H+]):calcd for C11H10N2S2Cl,268.9974,found268.9977.
实施例5
用1e代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000051
谱图解析数据3e:
1H NMR(CDCl3,500MHz):δ7.81–7.71(m,2H),7.66–7.56(m,2H),4.69(dd,J＝16.5,2.2,1H),4.46(dd,J＝16.6,7.9,1H),4.32(m,1H),3.23(dd,J＝13.4,6.5,1H),3.12(dd,J＝13.5,8.1,1H).13C NMR(CDCl3,125MHz):δ165.7,131.9,131.5,129.8,126.3,111.1,68.5,50.4,38.8.HRMS(ESI-TOF,[M+H+]):calcd for C11H10N2S2Br,312.9469,found312.9474.
实施例6
用1f代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000052
谱图解析数据3f:
1H NMR(CDCl3,500MHz):δ7.93(d,J＝8.1,2H),7.69(d,J＝8.2,2H),4.67(dd,J＝16.7,2.3,1H),4.45(dd,J＝16.7,7.9,1H),4.30(m,1H),3.18(dd,J＝13.5,6.6,1H),3.07(dd,J＝13.5,8.0,1H).13C NMR(CDCl3,125MHz):δ165.5,135.7,133.2(q,J＝32.9),128.7,125.6,125.6,123.6(q,J＝272.6),111.1,68.7,50.5,38.8.HRMS(ESI-TOF,[M+H+]):calcdfor C12H10N2F3S2,303.0237,found 303.0244.
实施例7
用1g代替实例1中的1a，其他条件同实例1,实验结果见表1。
Figure GDA0002916071040000061
谱图解析数据3g:
1H NMR(CDCl3,500MHz):δ7.51(dd,J＝5.2,1.1,1H),7.45(dd,J＝3.8,1.1,1H),7.11(dd,J＝5.1,3.7,1H),4.59(dd,J＝16.3,2.0,1H),4.38(dd,J＝16.3,7.6,1H),4.27(m,1H),3.18(dd,J＝13.4,6.6,1H),3.08(dd,J＝13.4,8.1,1H).13C NMR(CDCl3,125MHz):δ159.9,136.2,131.3,130.5,127.7,111.2,67.9,51.0,38.7.HRMS(ESI-TOF,[M+H+]):calcdfor C9H9N2S2,240.9928,found 240.9931.
实施例8
用1h代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000062
谱图解析数据3h:
1H NMR(CDCl3,500MHz):δ8.64(m,1H),8.05(dd,J＝7.9,1.2,1H),7.78(m,1H),7.38(m,1H),4.71(dd,J＝16.9,2.3,1H),4.49(dd,J＝16.9,8.1,1H),4.16(m,1H),3.18(dd,J＝13.4,6.3,1H),3.04(dd,J＝13.4,8.4,1H).13C NMR(CDCl3,125MHz):δ169.4,150.5,149.4,136.7,125.8,121.6,111.4,68.9,48.5,39.0.HRMS(ESI-TOF,[M+Na+]):calcd for C10H9N3NaS2,258.0136,found 258.0139.
实施例9
用1i代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000071
谱图解析数据3i:
1H NMR(CDCl3,500MHz):δ7.82–7.76(m,2H),7.55–7.51(m,1H),7.50–7.42(m,7H),4.91(dd,J＝16.3,3.6,1H),4.79(ddd,J＝10.7,8.1,3.6,1H),4.68(dd,J＝16.3,8.1,1H),4.36(d,J＝10.5,1H).13C NMR(CDCl3,125MHz):δ137.8,132.5,131.6,129.4,129.2,128.6,128.3,127.7,110.2,68.4,56.5,54.6.HRMS(ESI-TOF,[M+H+]):calcd for C17H15N2S2,311.0677,found 311.0680.
实施例10
用1j代替实例1中的1a，其他条件同实例1，实验结果见表1。
Figure GDA0002916071040000072
谱图解析数据3j:
1H NMR(CDCl3,500MHz):δ7.89–7.77(m,2H),7.51(t,J＝7.4,1H),7.48–7.41(m,4H),7.41–7.35(m,3H),4.92(d,J＝16.1,1H),4.56(d,J＝16.1,1H),3.67(m,2H).13C NMR(CDCl3,125MHz):δ167.4,138.8,132.7,131.8,129.2,128.7,128.6,128.3,127.1,111.6,73.4,69.3,46.9.HRMS(ESI-TOF,[M+H+]):calcd for C17H15N2S2,311.0677,found311.0683.
表1
Figure GDA0002916071040000081

Claims (2)

1.一种含硫氰基噻唑啉类化合物的制备方法，所述含硫氰基噻唑啉类化合物具有式Ⅰ所示的结构：
Figure FDA0002933382780000011
式Ⅰ中，其中R1选自苯基、4-甲基苯基、4-甲氧基苯基、4-氯苯基、4-溴苯基、4-三氟甲基苯基、2-噻吩基、2-吡啶基且R2，R3选自H；或者R1，R2选自苯基且R3选自H；或者R1，R3选自苯基且R2选自H；其特征在于，向反应器中加入摩尔比为1：2的硫代酰胺与硫氰酸铵，加入乙腈作为溶剂，在电的作用下，室温下搅拌反应，反应方程式如下：
Figure FDA0002933382780000012
2.按照权利要求1所述的制备方法，其特征在于：电极为石墨棒，溶剂为乙腈，反应时间为5h，恒压2V。
CN201911350702.1A 2019-12-24 2019-12-24 一种含硫氰基噻唑啉类化合物的制备方法 Active CN111072588B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911350702.1A CN111072588B (zh) 2019-12-24 2019-12-24 一种含硫氰基噻唑啉类化合物的制备方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911350702.1A CN111072588B (zh) 2019-12-24 2019-12-24 一种含硫氰基噻唑啉类化合物的制备方法

Publications (2)

Publication Number Publication Date
CN111072588A CN111072588A (zh) 2020-04-28
CN111072588B true CN111072588B (zh) 2021-03-30

Family

ID=70317416

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911350702.1A Active CN111072588B (zh) 2019-12-24 2019-12-24 一种含硫氰基噻唑啉类化合物的制备方法

Country Status (1)

Country Link
CN (1) CN111072588B (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111138378A (zh) * 2020-01-17 2020-05-12 浙江农林大学暨阳学院 一种银催化制备2-苯基-5-苯基-5-甲硫氰基-4,5-二氢噻唑类化合物的方法
CN111925339A (zh) * 2020-05-29 2020-11-13 诸暨市人民医院 一种制备肿瘤抑制剂多取代4,5-二氢噻唑类化合物的方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404070A (en) * 1982-07-23 1983-09-13 Celanese Corporation Electrochemical production of 2,6-diaminobenzobisthiazole
JPS63211285A (ja) * 1987-02-27 1988-09-02 Taiho Yakuhin Kogyo Kk ２β−置換メチルペニシリン誘導体の製造法
CN103741163A (zh) * 2013-12-20 2014-04-23 哈尔滨理工大学 一种2-氯-5-氯甲基-1,3-噻唑的合成方法
CN109338402A (zh) * 2018-11-29 2019-02-15 福建医科大学 一种水中电催化苯并硫代酰胺类化合物合成苯并噻唑的方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404070A (en) * 1982-07-23 1983-09-13 Celanese Corporation Electrochemical production of 2,6-diaminobenzobisthiazole
JPS63211285A (ja) * 1987-02-27 1988-09-02 Taiho Yakuhin Kogyo Kk ２β−置換メチルペニシリン誘導体の製造法
CN103741163A (zh) * 2013-12-20 2014-04-23 哈尔滨理工大学 一种2-氯-5-氯甲基-1,3-噻唑的合成方法
CN109338402A (zh) * 2018-11-29 2019-02-15 福建医科大学 一种水中电催化苯并硫代酰胺类化合物合成苯并噻唑的方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Access to SCN-containing thiazolines via electrochemical regioselective thiocyanothiocyclization of N-allylthioamides;Yan-An Zhang等;《Org. Chem. Front.》;20200409;第7卷;第1321-1326页 *
Qumruddeen等.Lewis Base/Brønsted Acid Cocatalysis for Thiocyanation of Amides and Thioamides.《J. Org. Chem.》.2020,第85卷 *
Transition-Metal-Free Tandem Radical Thiocyanooxygenation of Olefinic Amides: A New Route to SCN-Containing Heterocycles;Hua Yang等;《Org. Lett.》;20150403;第17卷;第1998-2001页 *

Also Published As

Publication number Publication date
CN111072588A (zh) 2020-04-28

Similar Documents

Publication Publication Date Title
CN111072588B (zh) 一种含硫氰基噻唑啉类化合物的制备方法
CN107573267B (zh) 含有三氟甲基的烷基磺酰氟化合物、其制备方法和应用
CN110240568B (zh) 三取代哒嗪类衍生物及其制备方法
CN109053618B (zh) 一种噁唑衍生物的制备方法
CN113735751B (zh) 一种制备芳基异硫脲的方法
CN108373453A (zh) 三氮唑衍生物及其制备方法
HU198939B (en) Process for producing neopodophyllotoxin benzylether derivatives
NL2029460B1 (en) Tetrahydrofuroindole compound and preparation method and application thereof
CN110105269B (zh) 基于非对称炔的1,4-二离子型含硫内鎓盐衍生物及其制备方法
CN113881956A (zh) 一种异硫氰酸苄酯类化合物的制备方法
CN104610267B (zh) 无催化条件下高效的合成6-烷基吡唑并[1,5-c]喹唑啉骨架化合物的方法
CN110105285B (zh) 三取代吡唑类衍生物及其制备方法
Kumar et al. A new approach for the transformation of alkenes to pyrrolines via aziridine intermediates
CN108689892A (zh) 3-磺酰化-二氢茚酮类化合物及其制备方法
CN111362795B (zh) 一类取代丁酸酯类衍生物的制备方法
CN109160886B (zh) 一种n-苯基苯甲酰胺合成方法
CN113372353A (zh) 一种二氟烷基化的二氢呋喃喹啉酮衍生物及其制备方法
CN111235596A (zh) 一种含硒噻唑啉类化合物的制备方法
CN112745275B (zh) 1,3,4-恶二唑杂环化合物的合成方法
CN112500368A (zh) 1,3,4-噻二唑类衍生物及其制备方法
CN107200729B (zh) 一种4-（2-甲氧基苯基）-5-（2-吡啶基)-3-氨基异恶唑的制备方法
MURTHY et al. NEW HYPOGLYCEMIC AGENTS: SYNTHESIS AND HYPOGLYCEMIC ACTIVITY OF SOME NEW 1-[{p-(4-OXO-2-SUBSTITUTED-3 (4H)-QUINAZOLINYL)-PHENYL} SULPHONYL]-3-ARYL/CYCLOHEXYL-2-THIOUREAS
CN112725824A (zh) 一种含亚胺二氢噻吩类化合物的制备方法
CN114181182B (zh) 一种多取代的4h-吡喃类化合物的合成方法
CN111393437B (zh) 三取代吲嗪类化合物及其制备方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant